CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 88 enrolled
Drug / intervention
AZD6244 +2 moredrug
Likely dose
AZD6244 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00890825
NCT00890825Phase 2Completed
CompareCT.gov

Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic NSCLC

AstraZeneca·interventional·Posted Apr 30, 2009·Updated Jun 20, 2018

In Brief

A Phase 2 clinical trial evaluating AZD6244, docetaxel, and 1 other intervention for Non Small Cell Lung Cancer. Completed, enrolled 88 participants across 63 sites in 12 countries.

Detailed Summary

The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesBelgium, Brazil, Bulgaria, Canada, Czechia, France, Hungary, Italy, Mexico, Peru, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 30, 2009
Enrollment StartApr 20, 2009
Primary CompletionMay 11, 2011
Study CompletionNov 2, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.2 years ago

Interventions

AZD6244drug

oral capsules, 75mg twice daily

docetaxeldrug

75mg/m2 iv on day 1 of every 21 day cycle

Placebodrug

placebo